Mir Aadil, Devendran Alagarsamy, S. Athinarayanan, Mohd Azhar et al.
A. Dharmadhikari, P. K. Chaurasia, Yash Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. Objectives This subgroup analysis of an Indian Phase 3 study was conducted to evaluate the efficacy and safety of Lumatepero...
A. Dharmadhikari, P. K. Chaurasia, Yash Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug approved for Bipolar II depression in 2021, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. Objectives This post-hoc analysis of an Indian Phase 3 study was conducted to eva...
Ashwin Dharmadhikari, P. K. Chaurasia, Yogita S. Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. Objectives This post-hoc analysis of an Indian Phase 3 study was conducted to evaluate the impact of Lumateperone 42mg compa...
Ashwin Dharmadhikari, P. K. Chaurasia, Yash Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug approved in 2021 for bipolar depression, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. In India, Quetiapine is one of the approved drugs for use in depressive episodes for...
A. Dharmadhikari, P. K. Chaurasia, Yash Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. Objectives This subgroup analysis of an Indian Phase 3 study was conducted to evaluate the efficacy and safety of Lumatepero...
A. Dharmadhikari, P. K. Chaurasia, Yash Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. Objectives This subgroup analysis of an Indian Phase 3 study was conducted to evaluate the efficacy and safety of Lumatepero...
A. Dharmadhikari, P. K. Chaurasia, Yash Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug approved for Bipolar II depression in 2021, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. Objectives This subgroup analysis of an Indian Phase 3 study was conducted to eva...
Ashwin Dharmadhikari, P. K. Chaurasia, Yash Patel, Devendra Kumar Choudhary et al.
Introduction Lumateperone, an atypical antipsychotic drug approved in 2021 for bipolar depression, has a dual mechanism of action by combination of activity at central serotonin (5-HT2A) and dopamine (D2) receptors. In India, Quetiapine is one of the approved drugs for use in depressive episodes for...